Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20:1382-1386

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kamphuisen, P. W.
Right arrow Articles by Bertina, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kamphuisen, P. W.
Right arrow Articles by Bertina, R. M.
Related Collections
Right arrow Coagulation and fibronolysis
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20:1382.)
© 2000 American Heart Association, Inc.


Thrombosis

Factor V Antigen Levels and Venous Thrombosis

Risk Profile, Interaction With Factor V Leiden, and Relation With Factor VIII Antigen Levels

P. W. Kamphuisen; F. R. Rosendaal; J. C. J. Eikenboom; R. Bos; R. M. Bertina

From the Hemostasis and Thrombosis Research Center (P.W.K., F.R.R., J.C.J.E., R.M.B.) and the Department of Clinical Epidemiology (F.R.R.), Leiden University Medical Center, and the Gaubius Laboratory (R.B.), TNO Prevention and Health, Leiden, the Netherlands. Dr Bos is now at Pharming Technologies, Leiden, the Netherlands.

Correspondence to Rogier M. Bertina, Hemostasis and Thrombosis Research Center, Leiden University Medical Center, C2-R, PO Box 9600, 2300 RC Leiden, Netherlands. E-mail bertina{at}hematology.azi

Abstract—Clotting factor V has a dual function in coagulation: after activation, procoagulant factor V stimulates the formation of thrombin, whereas anticoagulant factor V acts as a cofactor for activated protein C (APC) in the degradation of factor VIII/VIIIa, thereby reducing thrombin formation. In the present study, we evaluated whether plasma factor V levels, either decreased or increased, are associated with venous thrombosis. High procoagulant factor V levels may enhance prothrombinase activity and increase the thrombosis risk. Low anticoagulant factor V levels could reduce APC-cofactor activity in the factor VIII inactivation (APC-resistant phenotype), which might also promote thrombosis. Low factor V levels in combination with factor V Leiden could lead to a more severe APC-resistant phenotype (pseudohomozygous APC resistance). To address these issues, we have measured factor V antigen (factor V:Ag) levels in 474 patients with thrombosis and 474 control subjects that were part of the Leiden Thrombophilia Study (LETS). Factor V:Ag levels increased by 7.6 U/dL for every successive 10 years of age. Mean factor V:Ag levels were 134 (range 41 to 305) U/dL in patients and 132 (range 47 to 302) U/dL in controls. Neither high nor low factor V:Ag levels were associated with venous thrombosis. We found that factor V:Ag and factor VIII antigen levels in plasma were correlated, but factor V did not modify the thrombotic risk of high factor VIII levels. The normalized APC ratio was not influenced by the factor V:Ag level in subjects with or without factor V Leiden. We conclude that neither low nor high factor V:Ag levels are associated with venous thrombosis and that factor V:Ag levels do not mediate the thrombotic risk associated with high factor VIII levels.


Key Words: factor V • venous thrombosis • factor V Leiden • factor VIII




This article has been cited by other articles:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
D. Scanavini, D. Girelli, B. Lunghi, N. Martinelli, C. Legnani, M. Pinotti, G. Palareti, and F. Bernardi
Modulation of Factor V Levels in Plasma by Polymorphisms in the C2 Domain
Arterioscler Thromb Vasc Biol, January 1, 2004; 24(1): 200 - 206.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. R. Folsom, M. Cushman, M. Y. Tsai, N. Aleksic, S. R. Heckbert, L. L. Boland, A. W. Tsai, N. D. Yanez, and W. D. Rosamond
A prospective study of venous thromboembolism in relation to factor V Leiden and related factors
Blood, April 15, 2002; 99(8): 2720 - 2725.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
G. A.F. Nicolaes and B. Dahlback
Factor V and Thrombotic Disease: Description of a Janus-Faced Protein
Arterioscler Thromb Vasc Biol, April 1, 2002; 22(4): 530 - 538.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
A. Tripodi and P. M. Mannucci
Laboratory Investigation of Thrombophilia
Clin. Chem., September 1, 2001; 47(9): 1597 - 1606.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
P. W. Kamphuisen, J. C. J. Eikenboom, and R. M. Bertina
Elevated Factor VIII Levels and the Risk of Thrombosis
Arterioscler Thromb Vasc Biol, May 1, 2001; 21(5): 731 - 738.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
G. A.F. Nicolaes and B. Dahlback
Factor V and Thrombotic Disease: Description of a Janus-Faced Protein
Arterioscler Thromb Vasc Biol, April 1, 2002; 22(4): 530 - 538.
[Abstract] [Full Text] [PDF]